ALPPS 十周年:经验教训与未来方向
本文总结联合肝脏分隔和门静脉结扎的二步肝切除(ALPPS)十年发展。精确肝脏解剖知识是成功关键,部分、迷你或腹腔镜等微创化改良可提升安全性;纤维化/肝硬化肝脏增生程度低于非肝硬化。唯一前瞻性随机对照试验显示ALPPS切除率显著更高,围术期并发症与死亡率与传统二步肝切除联合门静脉栓塞相似,且门静脉栓塞失败后仍有效。
要点
- 精确掌握肝脏解剖及变异是ALPPS成功的首要条件。
- 部分、迷你或腹腔镜ALPPS等微创化改良与安全性提升相关。
- 唯一前瞻性随机对照试验显示ALPPS切除率更高,围术期并发症与死亡率相似。
核心结论
- ALPPS已成为成熟的二步肝切除术式,但仍需更多数据细化适应证与技术细节。
- 需长期肿瘤学结局结果来确定ALPPS在初始不可切除肝脏肿瘤患者中的地位。
研究设计与样本
- 基于2017年欧洲非洲肝胰胆协会双年会专家会议「ALPPS十周年」的现状总结报告。
主要发现
- 精确肝脏解剖及变异知识对ALPPS成功至关重要。
- 部分、迷你或腹腔镜等微创化改良主要旨在减少一期手术创伤,与安全性改善相关。
- 纤维化/肝硬化肝脏ALPPS术后未来肝剩余增生程度似乎低于非肝硬化肝脏。
- 唯一前瞻性随机对照试验显示ALPPS切除率显著更高,围术期并发症与死亡率与传统二步肝切除联合门静脉栓塞相似。
- ALPPS即使在门静脉栓塞失败后仍可靠有效。
临床怎么用
- 术前应精确评估肝脏解剖及变异以保障ALPPS成功。
- 可优先考虑部分、迷你或腹腔镜等微创化改良以提升安全性。
- 对纤维化/肝硬化肝脏应预期未来肝剩余增生程度可能低于非肝硬化肝脏。
- 门静脉栓塞失败后仍可考虑ALPPS。
局限性
- 长期肿瘤学结局数据尚缺乏,ALPPS在初始不可切除肝脏肿瘤中的定位未确立。
- 适应证与技术细节仍需进一步数据细化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Associating Liver Partition and Portal vein ligation for Staged hepatectomy (ALPPS) has been tested in various indications and clinical scenarios, leading to steady improvements in safety. This report presents the current status of ALPPS. SUMMARY BACKGROUND DATA: ALPPS offers improved resectability, but drawbacks are regularly pointed out regarding safety and oncologic benefits. METHODS: During the 12th biennial congress of the European African-Hepato-Pancreato-Biliary Association (Mainz, Germany, May 23-26, 2017) an expert meeting "10th anniversary of ALPP" was held to discuss indications, management, mechanisms of regeneration, as well as pitfalls of this novel technique. The aim of the meeting was to make an inventory of what has been achieved and what remains unclear in ALPPS. RESULTS: Precise knowledge of liver anatomy and its variations is paramount for success in ALPPS. Technical modifications, mainly less invasive approaches like partial, mini- or laparoscopic ALPPS, mostly aiming at minimizing the extensiveness of the first-stage procedure, are associated with improved safety. In fibrotic/cirrhotic livers the degree of future liver remnant hypertrophy after ALPPS appears some less than that in noncirrhotic. Recent data from the only prospective randomized controlled trial confirmed significant higher resection rates in ALPPS with similar peri-operative morbidity and mortality rates compared with conventional 2-stage hepatectomy including portal vein embolization. ALPPS is effective reliably even after failure of portal vein embolization. CONCLUSIONS: Although ALPPS is now an established 2-stage hepatectomy additional data are warranted to further refine indication and technical aspects. Long-term oncological outcome results are needed to establish the place of ALPPS in patients with initially nonresectable liver tumors.
引用
- Lang H, de Santibañes E, Schlitt HJ, et al. 10th Anniversary of ALPPS-Lessons Learned and quo Vadis. Ann Surg. 2019. PMID: 29727331. doi:10.1097/SLA.0000000000002797
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。